|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/17/2012 8:04:48 AM
Samsung Electronics’ aspirations to find a new growth engine in biotechnology and pharmaceuticals appear to have hit a speed bump. Company officials admit that it has halted clinical tests for SAIT101, a material it hoped would create more effective drugs to fight Hodgkin’s disease. ``We have been conducting clinical tests for SAIT101 in our labs in different locations around the word since March last year. However, the testing has stopped due to some internal reasons,’’ said one Samsung source, asking not be identified. The company had been testing the potential drug material with scientists in 16 countries, including Britain, Spain, Czech Republic, Canada, Brazil, South Africa and Taiwan aside of Korea. It appears that Samsung is being forced to redo the tests from scratch due to changes in safety requirements in Europe and the United States. The U.S. in particular has recently announced new guidelines for the research of biopharmaceuticals, or medical drugs produced using biotechnology. The Samsung source, who is close to the projects, said that the company is in talks with the U.S. Food and Drug Administration to reset the conditions for the SAIT101 clinical tests. ``We had vowed to get quicker approval in Europe, so this will definitely put us behind our original schedule. There was also a need to better prepare for testing in the U.S. which is even a larger market. We will eventually be fine,’’ he said.
|
|
|
|
|
|
|
|
|
|
|